Q4 FY26 ASX Investor Presentation
Filed with ASX · · 17 pages · English
In the deck
Earlier from Orthocell
- Orthocell Appoints Thailand Distributor for Remplir
- Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine
- First Sales of Remplir Achieved in US$75m Canadian Market
- Compelling 90% Success Rate for Remplir in Real World Study
- Q3 FY26 Investor Presentation
Later from Orthocell
- Orthocell Achieves First Remplir Sales in Thailand
- Remplir Shows Excellent Early Prostatectomy Results
- Quarterly Activity Report & Appendix 4C
- Q1 FY27 OCC Investor Presentation
- Strongest U.S. Remplir Sales Month Since Launch
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell